Melphalan: A potential new agent in the treatment of childhood rhabdomyosarcoma

J. A. Houghton, R. L. Cook, P. J. Lutz, P. J. Houghton

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Melphalan has been evaluated against a series of seven childhood rhabdomyosarcomas, each derived from a different patient and maintained in vivo as xenografts in immune-deprived mice. Six lines were derived from untreated tumors and one from a patient refractory to conventional therapy. At the maximum tolerated dose (LD10) a single administration of melphalan caused complete regressions of advanced tumor in six of seven lines, including xenografts derived from the refractory patient. This agent demonstrated activity over a broad range of doses, and was considerably more active than vincristine, cyclophosphamide, doxorubicin, and dactinomycin in the model.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalCancer Treatment Reports
Volume69
Issue number1
StatePublished - Jan 1 1985
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this